Poly(ester amide)-based drug delivery systems

• US 8,865,189 B2
• Filed: 12/31/2012
• Issued: 10/21/2014
• Est. Priority Date: 02/28/2006
• Status: Active Grant

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Kleiner, Lothar Walter, Pacetti, Stephen Dirk, Hossainy, Syed Faiyaz Ahmed, Trollsas, O. Mikael, Ngo, Michael Huy, DesNoyer, Jessica Rene
• Primary Examiner(s): Wax, Robert A
• Assistant Examiner(s): Singh, Randeep
• Application Number:
  US13/731,875
• Publication Number:
  US 20130129794A1
• Time in Patent Office: 659 Days
• Field of Search: None
• US Class Current: 424/400
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2420/02 Methods for coating medical devices
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

Implantable medical devices including a coating having a bioactive agent and a poly(ester amide) polymer. Methods of forming these coatings are also described.

Claims

1. An implantable device comprising a coating comprising a bioactive agent and a poly(ester amide) polymer, the poly(ester amide) polymer formed from L-leucine, cyclohexanediol, straight chain hexanediol, and sebacic acid.

2. The implantable device of claim 1, which is a stent.

3. The implantable device of claim 1, wherein the poly(ester amide) polymer is of the formula:

4. The implantable device of claim 1, wherein the bioactive agent is selected from the group consisting of rapamycin, everolimus, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, docetaxel, paclitaxel, and combinations thereof.

5. The implantable device of claim 3, wherein the bioactive agent is selected from the group consisting of rapamycin, everolimus, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, docetaxel, paclitaxel, and combinations thereof.

6. The implantable device of claim 4, wherein the bioactive agent is everolimus, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), or a combination thereof.

7. The implantable device of claim 5, wherein the bioactive agent is everolimus, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), or a combination thereof.